United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS Health

Moderna

Novavax

Check out these health care stocks that are heating up in the stock market right now.

4 Top Health Care Stocks To Watch In The Stock Market Today

All UK citizens over 18 will be offered a COVID-19 booster vaccine to deal with the potential impact of the omicron variant, the UK's vaccine advisory body the Joint Committee on Vaccine and Immunisation (JCVI) said today. It is a rapid step forward for a mutation that was only identified last week, but such in the concern surrounding the potential impact of the new strain spreading globally.

Omicron: All UK adults to get Pfizer of Moderna booster

Pfizer CEO Albert Bourla said he has a “very high level of confidence” that the company's Covid treatment pill is effective against the omicron variant.

Pfizer CEO confident Covid treatment pill will be effective against omicron variant

AstraZeneca

BioNTech SE

Johnson & Johnson

Fears about the Omicron variant of Covid-19 rattled the world's financial markets Friday and early Monday morning. But shares of the major coronavirus vaccine makers were getting a boost from the latest pandemic jitters.

Covid vaccine makers' stocks soar on Omicron variant concerns

Bristol-Myers

Eli Lilly

Dividend boosts in the latter half of November were as expected, but with some surprises.

High Doses Of Dividend Growth Expected From Pfizer, Eli Lilly, Bristol Myers In December

Albertsons Companies

Colgate-Palmolive

Clorox

While most everyone in the scientific community suspected that cases of COVID-19 would spike as we got closer to winter in the northern and the eastern parts of the country, similar to the spike in the South during the summer, most of the pundits were not expecting a new variant from South Africa to pop up.

5 Dividend Stocks Could Be Big Winners After the New COVID-19 Variant Shock

The omicron variant should gives these top vaccine stocks a healthy boost this week.

Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week

Apple

American Express

Citigroup

Caterpillar

Celsius Holdings

Dow Inc

Enphase Energy

Gritstone Oncology Inc

GlaxoSmithKline

Intel

Intrepid Potash

McDonald's

Microsoft

Procter & Gamble

Trillium Therapeutics

Travelers

Vir Biotechnology

Walmart

Two sample Breakout Stocks for Week 48 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfolio is up +70.5% YTD despite a record high 26 weeks out 47 weeks this year in negative conditions above the 40 MG level.

Week 48 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge

JPMorgan Chase & Co

These businesses should do extremely well next year, and their stocks will probably reflect that performance.

2 No-Brainer Buys for 2022

Kroger

Lakeland Industries

SPDR S&P 500 ETF Trust

Zoom Video

Stocks sold off sharply on Black Friday with concerns over a new Covid variant adding to macro uncertainties. The potential for new travel restrictions or return of social distancing measures represents a deeply bearish development for the market with risks tilted to the downside.

Specter Of New Covid Lockdowns Can Lift These 5 Stocks

Pfizer expects to know within two weeks whether the variant is resistant to its current vaccine, a company spokesperson told Reuters.

Pfizer said an updated version of its COVID-19 vaccine will be 'ready in 100 days' if the new Omicron variant is resistant to its current vaccine

The latest new variant of COVID-19 originated in South Africa. The World Health Organization has designated this new variant, called B.1.1.529, a "variant of concern." At least one new case of the new variant has been identified in Europe and all four cases found in Botswana infected fully vaccinated travelers who had been tested.

Pfizer Stock May Break Out On New COVID Variant

Pfizer and BioNTech said they expect more data from lab tests in two weeks at the latest.

Pfizer-BioNTech investigating new Covid variant, while J&J say they are testing their vaccine against it

DocuSign

Peloton

Little is known about the new COVID strain emerging in Africa. That hasn't stopped traders from betting big on lockdowns and a return to telework.

Forget reopening. The new COVID variant has 'stay-at-home' stocks rebounding.

The stock prices of vaccine makers Moderna and Pfizer surged Friday along with stay-at-home stocks like Zoom Video and Peloton.

Pandemic-related stocks from Zoom to Moderna jump as new coronavirus variant raises alarms and triggers lockdowns

The B.1.1.529 variant has been detected in South Africa, Botswana, Hong Kong, and Israel, and is spreading rapidly.

BioNTech says it will know in 2 weeks whether the COVID-19 vaccine it developed with Pfizer works against the new variant rapidly spreading in southern Africa

Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe

Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11

The stock price of Pfizer Inc. (NYSE: PFE) increased by over 6% pre-market today. This is why it happened.

Pfizer (PFE) Stock: Why The Price Jumped Today

The European Medicines Agency's (EMA) human medicines committee (CHMP) recommended using Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX)'s COVID-19 vaccine, Comirnaty, for children between 5 to 11. Pfizer-BioNTech's vaccine will be given in two 10-microgram doses three weeks apart as an injection in the upper arm, per the EMA recommendation.

Europe's CHMP Backs Pfizer/BioNTech's COVID-19 Shot For Kids Aged 5-11 Years

Move comes amid a fourth wave of coronavirus in Europe.

EU's drug regulator approves Pfizer vaccine for young children

It is the first time the regulator has authorized a Covid-19 vaccine for use in young children.

EU Regulator Clears Pfizer's Covid-19 Vaccine For Children Aged 5 To 11

News for Pfizer Stock (PFE)